StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Allergan (AGN) PT Cut To $189 At Wells Fargo After Rapastinel Misses Endpoints
March 7, 2019 8:55 AM
Wells Fargo analyst, David Maris, reiterated his Outperform rating on shares of Allergen (NYSE: AGN) and cut his PT to ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst PT Change
Next Articles
Allergan (AGN) Reports FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine
March 11, 2019 7:32 AM